Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy

NCT00297570 is registered in ClinicalTrials.gov with Sheba Medical Center as lead sponsor.

NCT NCT00297570
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00297570 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Imatinib Versus Imatinib and Peg-Interferon in Patients With Ph+ CML and Complete Cytogenetic Response After Imatinib Therapy
Lead sponsor
Sheba Medical Center
Phase
Phase 3
Overall status
Unknown status
Start date
February 28, 2006
Completion date
Not reported
Enrollment
90 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

leukemia, myeloid, philadelphia-positive